- Home
- WKSP vs PTN Comparison
WKSP vs PTN Comparison
Compare WKSP & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- PTN
- Stock Information
- Founded
- WKSP 2003
- PTN 1986
- Country
- WKSP United States
- PTN United States
- Employees
- WKSP N/A
- PTN N/A
- Industry
- WKSP Auto Parts:O.E.M.
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- PTN Health Care
- Exchange
- WKSP Nasdaq
- PTN Nasdaq
- Market Cap
- WKSP 22.0M
- PTN 20.9M
- IPO Year
- WKSP N/A
- PTN 1993
- Fundamental
- Price
- WKSP $3.33
- PTN $0.54
- Analyst Decision
- WKSP Strong Buy
- PTN Strong Buy
- Analyst Count
- WKSP 2
- PTN 1
- Target Price
- WKSP $15.75
- PTN $7.00
- AVG Volume (30 Days)
- WKSP 261.1K
- PTN 904.9K
- Earning Date
- WKSP 03-27-2025
- PTN 05-14-2025
- Dividend Yield
- WKSP N/A
- PTN N/A
- EPS Growth
- WKSP N/A
- PTN N/A
- EPS
- WKSP N/A
- PTN N/A
- Revenue
- WKSP $8,484,379.00
- PTN $350,000.00
- Revenue This Year
- WKSP $225.67
- PTN N/A
- Revenue Next Year
- WKSP $53.16
- PTN N/A
- P/E Ratio
- WKSP N/A
- PTN N/A
- Revenue Growth
- WKSP 454.67
- PTN N/A
- 52 Week Low
- WKSP $2.82
- PTN $0.46
- 52 Week High
- WKSP $12.00
- PTN $2.88
- Technical
- Relative Strength Index (RSI)
- WKSP 30.15
- PTN 28.90
- Support Level
- WKSP $3.11
- PTN $0.68
- Resistance Level
- WKSP $4.24
- PTN $0.84
- Average True Range (ATR)
- WKSP 0.59
- PTN 0.08
- MACD
- WKSP 0.06
- PTN -0.02
- Stochastic Oscillator
- WKSP 23.08
- PTN 20.22
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.